Verition Fund Management LLC Vertex Pharmaceuticals Inc Put Options Transaction History

Verition Fund Management LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $138,000 - $151,734	-300 Reduced 10.0%	2,700 $1.26 Million
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $157,124 - $194,212	400 Added 15.38%	3,000 $1.41 Million
Q1 2024 May 14, 2024	SELL	$407.69 - $446.08 $9.38 Million - $10.3 Million	-23,000 Reduced 89.84%	2,600 $1.09 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $8.45 Million - $9.06 Million	25,000 Added 4166.67%	25,600 $8.9 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $188,652 - $211,146	600 New	600 $211,000
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $5.7 Million - $6.36 Million	20,800 New	20,800 $6.02 Million
Q1 2022 May 13, 2022	BUY	$221.42 - $260.97 $575,692 - $678,522	2,600 Added 12.5%	23,400 $6.11 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $141,608 - $178,760	800 Added 4.0%	20,800 $4.57 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $3.63 Million - $4.06 Million	20,000 New	20,000 $3.63 Million

1,724

221M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

Stay updated on Verition Fund Management LLC with notifications on news.